DISEASE CONTROL AND CHANGES IN INDIVIDUAL TREATMENT OUTCOMES FROM WEEK 14 TO WEEK 52 WITH VEDOLIZUMAB OR ADALIMUMAB IN ULCERATIVE COLITIS: A VARSITY TRIAL POST HOC ANALYSIS

Stefan Schreiber  ¹     Silvio Danese  ²     Laurent Peyrin-Biroulet  ³     Jean-Frédéric Colombel  ⁴     Bruce E. Sands  ⁴     Dirk Lindner  ⁵     Richard A. Lirio  ⁶     Christian Agboton  ⁶     Edward V. Loftus Jr.  ^7    
1 University Hospital Schleswig-Holstein, Kiel, Germany
² Humanitas University, Milan, Italy
³ Nancy University Hospital, Nancy, France
⁴ Icahn School of Medicine at Mount Sinai, New York, United States
⁵ Takeda, Zurich, Switzerland
⁶ Takeda, Cambridge, United States
⁷ Mayo Clinic College of Medicine, Rochester, United States

Session
IBD (Posters)

Conference
UEG Week Virtual 2020

Citation
United European Gastroenterology Journal 2020; 8 (Supplement 1)